Search

Your search keyword '"Arat, Mutlu"' showing total 32 results

Search Constraints

Start Over You searched for: Author "Arat, Mutlu" Remove constraint Author: "Arat, Mutlu" Publisher american society of hematology Remove constraint Publisher: american society of hematology
32 results on '"Arat, Mutlu"'

Search Results

1. Risk Factors Influencing Transplant Outcomes of Adults with Acute Lymphoblastic Leukemia in First Complete Remission: A Retrospective Analysis from the ALWP of the EBMT

2. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics

3. Higher Efficacy of TBI + Cyclophosphamide Than TBI + Fludarabine As Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT

4. Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

5. Retrospective Comparison between 12-Gray and 8-Gray Total Body Irradiation (TBI) before Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia in First Complete Remission

6. Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT

8. Bone Marrow Versus Mobilized Peripheral Blood Stem Cells for Non T Depleted Haploidentical Transplantations with Post Transplantation Cyclophosphamide in Acute Lymphoblastic Leukemia: On Behalf of the ALWP of the EBMT

9. Outcome of Patients with Hodgkin Lymphoma Treated with Brentuximab Vedotin for Relapse after Autologous Stem Cell Transplant: A Retrospective Analysis of the LWP-EBMT

10. Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Lymphoblastic Leukemia: ALWP of the EBMT Study

11. Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients - the Diadem Study from the Chronic Malignancies Working Party of the EBMT

12. Metabolic Syndrome Is Common Following Haematopoietic Cell Transplantation (HCT) and Is Associated with Increased Cardiovascular Disease and Second Cancers: An EBMT Cross-Sectional Non-Interventional Study

13. Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors — a Retrospective Study By the EBMT Chronic Malignancies Working Party

14. Influence of Donor Type, Stem Cell Source and Conditioning Regimen on Transplant Outcomes after Haploidentical Transplant with Post Transplant Cyclophosphamide for Lymphoma: A Report of the EBMT Lymphoma Working Party

18. Paternity Wishes in Young Long-Term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation. A Study of the Late Effects Working Party of the EBMT

19. Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p

21. A Prospective Study on the Feasibility of Related and Unrelated Donor Search and Hematopoietic Cell Transplantation for Adults with Acute Leukemia at 31 European Transplant Centers

24. Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide (T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma.

26. Bronchiolitis Obliterans Syndrome after Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Survey of the Late Effect Working Party EBMT.

28. A New Predictive and Prognostic Marker for De Novo AML: Peripheral Blood CD34 (pCD34) Count at Recovery Following Remission Induction (RI) Therapy (Supp. by Ankara University-2003-0809114).

31. Both Higher Level of (bcr,abl) Transcripts and High Hasford Risk Score Are Associated with Cytogenetic Response but Absence of Molecular Remission during First Line Use of Imatinib Mesilate(IM): A Finding Not Observed Following Use among Interferon Failures.

Catalog

Books, media, physical & digital resources